Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies - PubMed (original) (raw)
Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies
M I New et al. J Clin Endocrinol Metab. 2001 Dec.
Abstract
Congenital adrenal hyperplasia (CAH) refers to a family of monogenic inherited disorders of adrenal steroidogenesis most often caused by enzyme 21-hydroxylase deficiency (21-OHD). In the classic forms of CAH (simple virilizing and salt wasting), androgen excess causes external genital ambiguity in newborn females and progressive postnatal virilization in males and females. Prenatal treatment of CAH with dexamethasone has been successfully used for over a decade. This article serves as an update on 532 pregnancies prenatally diagnosed using amniocentesis or chorionic villus sampling between 1978 and 2001 at New York Presbyterian Hospital-Weill Medical College of Cornell University. Of the 532 pregnancies, 281 were prenatally treated for CAH due to the risk of 21-hydroxylase deficiency. Follow-up telephone interviews with mothers, genetic counselors, endocrinologists, pediatricians, and obstetricians were performed in all cases. Of the pregnancies evaluated, 116 babies were affected with classic 21-OHD. Of these, 61 were female, 49 of whom were treated prenatally with dexamethasone. Dexamethasone administered at or before 9 wk gestation (in proper doses) was effective in reducing virilization. There were no statistical differences in the symptoms during pregnancy between mothers treated with dexamethasone and those not treated with dexamethasone, except for weight gain, edema, and striae, which were greater in the treated group. No significant or enduring side-effects were noted in the fetuses, indicating that dexamethasone treatment is safe. Prenatally treated newborns did not differ in weight from untreated, unaffected newborns. Based on our experience, prenatal diagnosis and proper prenatal treatment of 21-OHD are effective in significantly reducing or eliminating virilization in the newborn female. This spares the affected female the consequences of genital ambiguity, genital surgery, and possible sex misassignment.
Similar articles
- Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment.
Carlson AD, Obeid JS, Kanellopoulou N, Wilson RC, New MI. Carlson AD, et al. J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):19-29. doi: 10.1016/s0960-0760(99)00059-x. J Steroid Biochem Mol Biol. 1999. PMID: 10418977 Review. - Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency.
Mercado AB, Wilson RC, Cheng KC, Wei JQ, New MI. Mercado AB, et al. J Clin Endocrinol Metab. 1995 Jul;80(7):2014-20. doi: 10.1210/jcem.80.7.7608248. J Clin Endocrinol Metab. 1995. PMID: 7608248 - Prenatal diagnosis and treatment of 11beta-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia.
Cerame BI, Newfield RS, Pascoe L, Curnow KM, Nimkarn S, Roe TF, New MI, Wilson RC. Cerame BI, et al. J Clin Endocrinol Metab. 1999 Sep;84(9):3129-34. doi: 10.1210/jcem.84.9.5976. J Clin Endocrinol Metab. 1999. PMID: 10487675 - [Prenatal diagnosis and treatment of adrenogenital syndrome. Prevent virilization of female fetuses].
Lajic S, Bui TH, Holst M, Ritzén M, Wedell A. Lajic S, et al. Lakartidningen. 1997 Dec 10;94(50):4781-6. Lakartidningen. 1997. PMID: 9445959 Review. Swedish.
Cited by
- Clinical characteristics and treatment during preconception and perinatal period of infertile women with non-classical 21-hydroxylase deficiency.
Cui X, Li P. Cui X, et al. Reprod Health. 2024 Oct 1;21(1):139. doi: 10.1186/s12978-024-01874-2. Reprod Health. 2024. PMID: 39354633 Free PMC article. - Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency through molecular genetic analysis of the CYP21A2 gene.
Yoon JH, Hwang S, Kim JH, Kim GH, Yoo HW, Choi JH. Yoon JH, et al. Ann Pediatr Endocrinol Metab. 2024 Feb;29(1):54-59. doi: 10.6065/apem.2346014.007. Epub 2024 Feb 29. Ann Pediatr Endocrinol Metab. 2024. PMID: 38461806 Free PMC article. - An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia.
Van't Westeinde A, Karlsson L, Messina V, Wallensteen L, Brösamle M, Dal Maso G, Lazzerini A, Kristensen J, Kwast D, Tschaidse L, Auer MK, Nowotny HF, Persani L, Reisch N, Lajic S. Van't Westeinde A, et al. Endocr Connect. 2023 Mar 15;12(4):e220400. doi: 10.1530/EC-22-0400. Print 2023 Apr 1. Endocr Connect. 2023. PMID: 36752813 Free PMC article. Review. - Pregnancy and Prenatal Management of Congenital Adrenal Hyperplasia.
Cera G, Locantore P, Novizio R, Maggio E, Ramunno V, Corsello A, Policola C, Concolino P, Paragliola RM, Pontecorvi A. Cera G, et al. J Clin Med. 2022 Oct 19;11(20):6156. doi: 10.3390/jcm11206156. J Clin Med. 2022. PMID: 36294476 Free PMC article. Review. - Clinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision).
Ishii T, Kashimada K, Amano N, Takasawa K, Nakamura-Utsunomiya A, Yatsuga S, Mukai T, Ida S, Isobe M, Fukushi M, Satoh H, Yoshino K, Otsuki M, Katabami T, Tajima T. Ishii T, et al. Clin Pediatr Endocrinol. 2022;31(3):116-143. doi: 10.1297/cpe.2022-0009. Epub 2022 Apr 10. Clin Pediatr Endocrinol. 2022. PMID: 35928387 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical